目的：本研究目的在評估使用tamsulosin治療良性攝護腺肥大症之療效。材料及方法：總共30位攝護腺肥大症患者進入本試驗接受每日tamsulosin 0.2 mg治療。四週後分為三組：第一組維持原劑量繼續治療四周，第二組停藥四週，第三組增加為每日0.4mg。治療效果以國際攝護腺症狀評分，生活品質評分，及最大尿流速度評估。結果：二十七位患者有治療數據可供評估，19位在治療四週後有顯著改善。評估所有患者在治療四週後國際攝護腺症狀評分平均減輕7.7分，生活品質評分改善1.2分，最大尿流速度增加3.6毫升/秒。血壓變化在統計學上有意義，但臨床無意義。對0.2mg治療效果不佳的患者在劑量增加為每日0.4mg後有顯著改善，但血壓變化明顯。結論：根據我們有限的經驗，每日服用tamsulosin0.2mg似乎可有效治療良性攝護腺肥大症所導致之症狀並改善尿流速度；患者耐受性良好。

OBJECTIVE: The purpose of this open-label study was to assess the efficacy of tamsulosin hydrochloride in treating symptomatic benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: A total of 30 BPH patients was enrolled in this clinical trial with tamsulosin 0.2 mg once a day. After a 4-week initial treatment, patients were divided into 3 groups: 1) maintaining treatment for another 4 weeks, 2) discontinuing treatment for the following 4 weeks, and 3) doubling the dosage to 0.4 mg/day for 4 weeks. The efficacy of treatment was evaluated by International Prostatic Symptom Score (I-PSS), quality of life scores(QOL), and maximal urinary flow rate(Qmax). RESULTS: Twenty-seven patients had available follow-up data for analysis. Nineteen patients had significant response after 4-week treatment. When all patients were evaluated, mean decreases of I-PSS of 7.7 points and QOL of 1.2 points were noted at the 4-week visit. Qmax increased 3.6 ml/s over baseline values. Voided volume increased by 41 ml. A statistically but not clinically significant decrease in blood pressure was noted. For patients not responding to 0.2 mg tamsulosin, significant improvements in I-PSS and Qmax were achieved after increasing the dosage to 0.4 mg/day. However, significant decreases in systolic and diastolic blood pressure were encountered. CONCLUSIONS: In our series, tamsulosin hydrochloride 0.2 mg once a day was an effective treatment for symptomatic BPH with good tolerability.